The development of hybrid molecules that integrate distinct pharmacophores represents a valuable strategy in medicinal chemistry to enhance therapeutic potential. In this work, we describe the synthesis of 2-(4-isobutylphenyl)-N-(naphthalen-1-yl)propanamide, a novel amide derivative that combines the structural features of ibuprofen, a prototypical nonsteroidal anti-inflammatory drug (NSAID), with naphthalen-1-amine, an aromatic amine of pharmacological interest. The target compound was obtained via a single-step synthetic strategy employing dicyclohexylcarbodiimide (DCC) as a coupling reagent. Specifically, the carboxylic acid functionality of ibuprofen was activated in situ with DCC, enabling nucleophilic substitution by naphthalen-1-amine to afford the desired amide. The product was purified by recrystallization and chromatographic techniques, and its structure was confirmed using FTIR, ^1H NMR, ^13C NMR, and mass spectrometry.

This hybridization approach was designed to merge the anti-inflammatory pharmacophore of ibuprofen, known for cyclooxygenase (COX) inhibition, with the lipophilic naphthylamine scaffold, which could modulate binding interactions or pharmacokinetic behavior. The straightforward use of DCC-mediated amide bond formation demonstrates the efficiency of this method in generating novel derivatives without the need for multistep activation or protection strategies. While the current study emphasizes the synthesis and characterization of the compound, future investigations will explore its biological activity and potential improvements in anti-inflammatory efficacy compared to the parent drug.